{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:19:52Z","timestamp":1776244792145,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1016\/j.ygyno.2003.08.021","type":"journal-article","created":{"date-parts":[[2003,10,17]],"date-time":"2003-10-17T13:42:29Z","timestamp":1066398149000},"page":"596-602","source":"Crossref","is-referenced-by-count":61,"title":["Phase II trial of anastrozole in women with asymptomatic m\u00fcllerian cancer"],"prefix":"10.1016","volume":"91","author":[{"given":"Marcela G.del","family":"Carmen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlan F","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora K","family":"Horick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annekathryn","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda R","family":"Duska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Penson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael V","family":"Seiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2003.08.021_BIB1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","article-title":"Cancer statistics, 2001","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/jnci\/87.12.871","article-title":"Ovarian cancer","volume":"87","author":"McNeil","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0090-8258(85)90045-9","article-title":"Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer","volume":"22","author":"Hamerlynck","year":"1985","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ygyno.2003.08.021_BIB4","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1023\/A:1008308609325","article-title":"A randomized, open, parallel-group trial to compare endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer","volume":"10","author":"Vorobiof","year":"1999","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2003.08.021_BIB5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0300-2977(99)00030-3","article-title":"New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women","volume":"55","author":"deJong","year":"1999","journal-title":"Neth J Med"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB6","first-page":"32","article-title":"Emerging role of aromatase inhibitors in the treatment of breast cancer","volume":"12","author":"Harvey","year":"1998","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB7","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7","article-title":"Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma","volume":"83","author":"Buzdar","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.2001.19.3.881","article-title":"Aromatase inhibition in the treatment and prevention of breast cancer","volume":"19","author":"Goss","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB9","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB10","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125","volume":"14","author":"Rustin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB11","article-title":"Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma","volume":"24","author":"Gelman","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB12","first-page":"45","article-title":"Aromatase in human common epithelial ovarian neoplasms","volume":"149","author":"Kega","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0046-8177(89)90010-5","article-title":"Immunohistochemical studies of steroidogenic enzymes (aromatase, 17-\u03b1-hydroxylase and cholesterol side-chain cleavage cytochromes p-450) in sex cord-stromal tumors of the ovary","volume":"20","author":"Sasano","year":"1989","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB14","first-page":"2233","article-title":"CA125 response is associated with estrogen receptor expression in a Phase II trial of letrozole in ovarian cancer","volume":"8","author":"Bowman","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0090-8258(88)80026-X","article-title":"Steroid receptors and ovarian tumors","volume":"31","author":"Quinn","year":"1988","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2003.08.021_BIB16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0959-8049(94)90548-7","article-title":"Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma","volume":"30","author":"Veenhof","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00001813-200110000-00002","article-title":"Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer","volume":"12","author":"Sarikapan","year":"2001","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB18","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1200\/JCO.1993.11.10.1957","article-title":"Hormonal palliation of chemoresistant ovarian cancer","volume":"11","author":"Ahlgren","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O","article-title":"Responsiveness of patients with advanced ovarian cancer to tamoxifen","volume":"68","author":"Hatch","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1006\/gyno.1996.0181","article-title":"Tamoxifen in platinum-refractory ovarian cancer","volume":"62","author":"Markman","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2003.08.021_BIB21","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast cancer","volume":"92","author":"Boneterre","year":"2001","journal-title":"Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825803005766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825803005766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T09:58:06Z","timestamp":1550570286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825803005766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S0090825803005766"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2003.08.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}